4.48k followers • 19 symbols Watchlist by Motif Investing
Successful drug approvals by the FDA and innovations in the treatment of cancer could provide relevant stocks a boost.
Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol-Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $46.02, marking a -1.03% move from the previous day.
Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The fat lady is getting ready to sing with this big pharma deal. Celgene shareholders will soon have a decision to make.
Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
In a series of filings concerning the Pennsylvania-based bank over the past week, activists CT Opportunity Management and Driver Management disclosed that they had submitted proposed terms on March 23. The activist investors, filing together on April 4, reported that DNB Financial had declined to accept the term sheet.
The deal, announced in January, was a hard sell to Bristol shareholders from the start. The approval concludes a tumultuous period for Bristol, which saw pushback from institutional investors.
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Celgene shareholders also gave their support for the deal, which is expected to close in the third quarter but awaits US regulatory approval. “Together with Celgene, we will create a premier innovative biopharma company with leading scientific capabilities that is well positioned to address the needs of patients through high-value innovative medicines,” Bristol-Myers chairman and chief executive Giovanni Caforio said in a statement.
Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Akebia Therapeutics (AKBA) and Vifor Pharma expand licensing agreement related to commercialization of Akeba's pipeline candidate, vadadustat, to include additional dialysis organizations.
Columbia fund manager David King also likes a group of convertible preferred-stock issues, which offer higher yields than common shares.
Jeff Smith’s Starboard Value wrestled the crown from Elliott to become the most prolific activist investor in the first quarter of 2019, with new campaigns for a strategic rethink at companies as diverse as drugmaker Bristol-Myers Squibb, ecommerce business eBay and pizza chain Papa John’s. Starboard’s seven new campaigns eclipsed the four launched by Paul Singer’s Elliott Management, which was the most prolific for the previous seven consecutive quarters, and for 10 of the 11 previous quarters, according to data compiled by the boutique investment bank Lazard. Elliott still manages significantly more money — it has assets under management of more than $35bn, compared to Starboard’s $5.5bn, according to regulatory filings — but Starboard has been bolstering its reputation as a formidable opponent for companies it says are not being run to the maximum value for shareholders.
Bristol-Myers Squibb (BMY) closed the most recent trading day at $45.98, moving -1.73% from the previous trading session.
Inovio (INO) receives the third milestone payment from AstraZeneca post the initiation of dosing in a phase II combo study of the latter's MEDI0457 for HPV related anal, penile and vulvar cancers.
Bristol-Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.